On the public citation graph
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
0 signed · 301 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamaoncol.2015.6113openalex-snapshot
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes
inferredcites →https://doi.org/10.1016/j.ejca.2016.03.087openalex-snapshot
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up
inferredcites →https://doi.org/10.1016/s0140-6736(11)61847-3openalex-snapshot
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
inferredcites →https://doi.org/10.1016/s0140-6736(13)62422-8openalex-snapshot
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
inferredcites →https://doi.org/10.1016/s1470-2045(11)70336-9openalex-snapshot
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(13)70130-xopenalex-snapshot
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
inferredcites →https://doi.org/10.1016/s1470-2045(14)70080-4openalex-snapshot
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
inferredcites →https://doi.org/10.1016/s1470-2045(14)70320-1openalex-snapshot
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
inferredcites →https://doi.org/10.1016/s1470-2045(16)00163-7openalex-snapshot
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
inferredcites →https://doi.org/10.1038/bjc.2014.647openalex-snapshot
Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy
inferredcites →https://doi.org/10.1056/nejmoa0910383openalex-snapshot
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1113216openalex-snapshot
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1413513openalex-snapshot
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1703643openalex-snapshot
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
inferredcites →https://doi.org/10.1093/annonc/mdt182openalex-snapshot
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
inferredcites →https://doi.org/10.1093/annonc/mdt410openalex-snapshot
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)
inferredcites →https://doi.org/10.1158/0008-5472.can-03-3856openalex-snapshot
The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells
inferredcites →https://doi.org/10.1158/0008-5472.can-08-4597openalex-snapshot
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
inferredcites →https://doi.org/10.1158/0008-5472.sabcs11-s5-4openalex-snapshot
S5-4: pCR as a Surrogate in HER2−Positive Patients Treated with Trastuzumab.
inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-1760openalex-snapshot
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
inferredcites →https://doi.org/10.1186/bcr3690openalex-snapshot
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study
inferredcites →https://doi.org/10.1200/jco.20.5.1215openalex-snapshot
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
inferredcites →https://doi.org/10.1200/jco.2009.23.6950openalex-snapshot
Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831…
inferredcites →https://doi.org/10.1200/jco.2010.31.4930openalex-snapshot
Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
inferredcites →https://doi.org/10.1200/jco.2011.40.0010openalex-snapshot
Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2014.32.15_suppl.lba4openalex-snapshot
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).
inferredcites →https://doi.org/10.1200/jco.2015.61.8413openalex-snapshot
Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.5116048openalex-extracted
Comparative Long and Short-Term Efficacy and Safety of Pertuzumab Plus Trastuzumab Versus Trastuzumab Monotherapy in Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis of Six Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1001/jamaoncol.2021.1371openalex-snapshot
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2 -Positive Breast Cancer
inferred← citeshttps://doi.org/10.1002/cam4.70005openalex-snapshot
Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis
inferred← citeshttps://doi.org/10.1002/cam4.7325openalex-snapshot
Pathological and clinical outcomes following neoadjuvant dual HER2 therapy for early‐stage breast cancer: An Australian institutional real‐world experience
inferred← citeshttps://doi.org/10.1002/cncr.32873openalex-snapshot
Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer
inferred← citeshttps://doi.org/10.1002/cncr.34589openalex-snapshot
Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer
inferred← citeshttps://doi.org/10.1002/ijc.34245openalex-snapshot
Pertuzumab study in the neoadjuvant setting for HER2‐positive nonmetastatic breast cancer in Australia (PeRSIA)
inferred← citeshttps://doi.org/10.1002/ijc.70666openalex-snapshot
Anthracycline‐Free Neoadjuvant Therapy With Nab‐Paclitaxel and Carboplatin in Non‐Luminal Breast Cancer: A Single‐Arm Clinical Trial
inferred← citeshttps://doi.org/10.1002/jso.25814openalex-snapshot
Refining the indications for neoadjuvant chemotherapy for patients with HER2+ breast cancer: A single institution experience
inferred← citeshttps://doi.org/10.1002/jso.26236openalex-snapshot
Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de‐escalate surgical treatments
inferred← citeshttps://doi.org/10.1007/978-3-030-73147-2_16openalex-snapshot
Primary/Neoadjuvant Treatments
inferred← citeshttps://doi.org/10.1007/978-3-030-88020-0_1openalex-snapshot
Neoadjuvant Therapy for Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-88020-0_6openalex-snapshot
Neoadjuvant Systemic Therapy for Breast Cancer Based on Underlying Tumor Biology
inferred← citeshttps://doi.org/10.1007/978-3-319-96947-3_10openalex-snapshot
Preoperative Systemic Therapy for Non-Inflammatory Locally Advanced Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-96947-3_11openalex-snapshot
Inflammatory Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-96947-3_16openalex-snapshot
Adjuvant Therapy for HER2-Positive Early-Stage Breast Cancer
inferred← citeshttps://doi.org/10.1007/s00129-026-05484-wopenalex-snapshot
Neoadjuvante Therapie – Chancen der Therapieoptimierung
inferred← citeshttps://doi.org/10.1007/s00330-024-10857-7openalex-snapshot
Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer
inferred← citeshttps://doi.org/10.1007/s00761-021-01060-0openalex-snapshot
Therapiealgorithmen für das Mammakarzinom
inferred← citeshttps://doi.org/10.1007/s10534-025-00747-wopenalex-snapshot
Progress and prospects of metal-based immunotherapy in breast cancer
inferred← citeshttps://doi.org/10.1007/s10549-021-06166-yopenalex-snapshot
Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study
inferred← citeshttps://doi.org/10.1007/s10549-021-06172-0openalex-snapshot
A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006)
inferred← citeshttps://doi.org/10.1007/s10549-021-06266-9openalex-snapshot
Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study
inferred← citeshttps://doi.org/10.1007/s10549-022-06811-0openalex-snapshot
The impact of neoadjuvant systemic treatment on postoperative complications in breast cancer surgery
inferred← citeshttps://doi.org/10.1007/s10549-024-07333-7openalex-snapshot
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)
inferred← citeshttps://doi.org/10.1007/s10549-026-07895-8openalex-snapshot
Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer
inferred← citeshttps://doi.org/10.1007/s10549-026-07942-4openalex-snapshot
Neoadjuvant twelve weekly paclitaxel–carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer
inferred← citeshttps://doi.org/10.1007/s11523-022-00874-1openalex-snapshot
Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP)
inferred← citeshttps://doi.org/10.1007/s11864-019-0646-1openalex-snapshot
Cardiotoxicity of Contemporary Breast Cancer Treatments
inferred← citeshttps://doi.org/10.1007/s11864-021-00884-7openalex-snapshot
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles
inferred← citeshttps://doi.org/10.1007/s11864-023-01070-7openalex-snapshot
Individualizing Curative-Intent Therapy in HER2-Positive Early-Stage Breast Cancer
inferred← citeshttps://doi.org/10.1007/s11912-019-0842-yopenalex-snapshot
Inflammatory Breast Cancer: a Separate Entity
inferred← citeshttps://doi.org/10.1007/s11912-019-0848-5openalex-snapshot
When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab
inferred← citeshttps://doi.org/10.1007/s11936-019-0788-2openalex-snapshot
Cardiovascular Disease Risk in Survivors of Breast Cancer
inferred← citeshttps://doi.org/10.1007/s12094-024-03814-9openalex-snapshot
Inflammation-related biomarkers as predictors of pathological complete response in early-stage breast cancer
inferred← citeshttps://doi.org/10.1007/s12094-024-03838-1openalex-snapshot
Strategies to enhance management of HER2-positive breast cancer in the elderly: an expert consensus perspective
inferred← citeshttps://doi.org/10.1007/s12094-025-03937-7openalex-snapshot
Predictive factors for pCR and relapse following neoadjuvant dual HER2-blockade in HER2+ breast cancer: an international cohort study
inferred← citeshttps://doi.org/10.1007/s12094-026-04517-zopenalex-snapshot
Prognostic value of post-neoadjuvant pathological response and residual disease in early breast cancer: a real-world cohort study
inferred← citeshttps://doi.org/10.1007/s12254-022-00819-4openalex-snapshot
Neoadjuvant treatment in solid tumors—the earlier, the better in breast cancer
inferred← citeshttps://doi.org/10.1007/s13126-020-0550-yopenalex-snapshot
Enhancing the Critical Role of Core Needle Biopsy in Breast Cancer
inferred← citeshttps://doi.org/10.1007/s15015-018-4217-2openalex-snapshot
Kombinierte HER2-Blockade beim frühen Mammakarzinom langfristig verträglich
inferred← citeshttps://doi.org/10.1007/s40264-019-00886-3openalex-snapshot
Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study
inferred← citeshttps://doi.org/10.1007/s40265-020-01411-yopenalex-snapshot
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars
inferred← citeshttps://doi.org/10.1007/s40266-021-00889-9openalex-snapshot
Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients
inferred← citeshttps://doi.org/10.1007/s40487-021-00178-wopenalex-snapshot
Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature
inferred← citeshttps://doi.org/10.1007/s40487-025-00398-4openalex-snapshot
Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review
inferred← citeshttps://doi.org/10.1007/s41974-024-00340-yopenalex-snapshot
Was ist neu in der systemischen Behandlung des frühen Mammakarzinoms?
inferred← citeshttps://doi.org/10.1016/j.acra.2025.04.010openalex-snapshot
HER2 (2+)/SISH-positive vs. HER2 (3+) Breast Cancer: Pre-treatment MRI Differences and Accuracy of pCR Prediction on Post-treatment MRI
inferred← citeshttps://doi.org/10.1016/j.annonc.2021.04.011openalex-snapshot
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
inferred← citeshttps://doi.org/10.1016/j.annonc.2023.11.016openalex-snapshot
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
inferred← citeshttps://doi.org/10.1016/j.annonc.2025.07.016openalex-snapshot
Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials
inferred← citeshttps://doi.org/10.1016/j.breast.2020.10.003openalex-snapshot
Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.breast.2022.01.006openalex-snapshot
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
inferred← citeshttps://doi.org/10.1016/j.breast.2022.06.007openalex-snapshot
Anthracyclines in the treatment of early breast cancer friend or foe?
inferred← citeshttps://doi.org/10.1016/j.breast.2022.07.005openalex-snapshot
Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival
inferred← citeshttps://doi.org/10.1016/j.breast.2023.03.009openalex-snapshot
The role of the radiation therapy breast boost in the 2020s
inferred← citeshttps://doi.org/10.1016/j.breast.2023.07.008openalex-snapshot
Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy
inferred← citeshttps://doi.org/10.1016/j.breast.2023.103594openalex-snapshot
Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer
inferred← citeshttps://doi.org/10.1016/j.breast.2025.104669openalex-snapshot
Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy
inferred← citeshttps://doi.org/10.1016/j.breast.2026.104849openalex-snapshot
HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: A correlative analysis from a real-world cohort
inferred← citeshttps://doi.org/10.1016/j.clbc.2021.02.001openalex-snapshot
Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.clbc.2021.05.008openalex-snapshot
Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients
inferred← citeshttps://doi.org/10.1016/j.clbc.2023.07.006openalex-snapshot
Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper
inferred← citeshttps://doi.org/10.1016/j.clbc.2023.09.010openalex-snapshot
Neoadjuvant Chemotherapy of Taxanes With or Without Anthracyclines in Different Molecular Subtypes of Breast Cancer: A Propensity Score Matching Study
inferred← citeshttps://doi.org/10.1016/j.clbc.2024.07.002openalex-snapshot
Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide With Trastuzumab in Stage I-II Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.clbc.2024.10.005openalex-snapshot
A Clinical Review of Subcutaneous Trastuzumab and the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in the Treatment of HER2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.clbc.2024.11.006openalex-snapshot
Adjuvant Trastuzumab Plus Pertuzumab Versus Trastuzumab Alone in Patients Achieving Pathologic Complete Response After Chemotherapy With Trastuzumab and Pertuzumab: A Retrospective Cohort Study
inferred← citeshttps://doi.org/10.1016/j.clbc.2026.01.007openalex-snapshot
Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis
inferred← citeshttps://doi.org/10.1016/j.compbiomed.2023.107339openalex-snapshot
Mechanism of breast cancer immune microenvironment in prognosis of heart failure
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2022.103880openalex-snapshot
Three-year disease-free survival in randomized trials of neoadjuvant chemotherapy and HER2-targeted therapy in breast cancer: A meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ctarc.2021.100483openalex-snapshot
Neoadjuvant pertuzumab plus trastuzumab in combination with anthracycline- free chemotherapy regimen in patients with HER2 positive breast cancer–Real-world data from a single center in India
inferred← citeshttps://doi.org/10.1016/j.ctarc.2022.100670openalex-snapshot
Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba
inferred← citeshttps://doi.org/10.1016/j.ctarc.2023.100772openalex-snapshot
Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)
inferred← citeshttps://doi.org/10.1016/j.ctrv.2025.102901openalex-snapshot
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ctrv.2025.102975openalex-snapshot
Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ctrv.2025.103001openalex-snapshot
Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group
inferred← citeshttps://doi.org/10.1016/j.ejca.2019.07.015openalex-snapshot
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer
inferred← citeshttps://doi.org/10.1016/j.ejca.2022.05.009openalex-snapshot
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.ejca.2026.116882openalex-snapshot
Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study
inferred← citeshttps://doi.org/10.1016/j.ejogrb.2025.114041openalex-snapshot
Assessment of parameters associated with ovarian function recovery in premenopausal women with early breast cancer and chemotherapy-induced amenorrhea in real-world clinical practice
inferred← citeshttps://doi.org/10.1016/j.esmoop.2022.100461openalex-snapshot
Anthracyclines in the treatment of patients with early breast cancer
inferred← citeshttps://doi.org/10.1016/j.esmoop.2024.104100openalex-snapshot
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers
inferred← citeshttps://doi.org/10.1016/j.esmoop.2026.108541openalex-snapshot
Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial
inferred← citeshttps://doi.org/10.1016/j.hoc.2022.08.012openalex-snapshot
Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.humpath.2025.105825openalex-snapshot
Current concepts and controversies in post-neoadjuvant breast pathology
inferred← citeshttps://doi.org/10.1016/j.ijpharm.2018.07.055openalex-snapshot
Prussian blue nanoparticles: Synthesis, surface modification, and application in cancer treatment
inferred← citeshttps://doi.org/10.1016/j.jaccao.2024.07.016openalex-snapshot
Anthracycline Cardiotoxicity in Adult Cancer Patients
inferred← citeshttps://doi.org/10.1016/j.jare.2020.08.014openalex-snapshot
Update on systemic treatment for newly diagnosed inflammatory breast cancer
inferred← citeshttps://doi.org/10.1016/j.jddst.2025.107387openalex-snapshot
Stimuli-responsive iron-based metal-organic frameworks (Fe-MOFs) for drug delivery and theranostics in breast cancer: A critical review
inferred← citeshttps://doi.org/10.1016/j.neo.2026.101318openalex-snapshot
Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer
inferred← citeshttps://doi.org/10.1016/j.tranon.2024.102173openalex-snapshot
An exploration of the optimal combination chemotherapy regimen based on neoadjuvant therapy containing pyrotinib for HER2-positive breast cancer: A multicenter real-world study
inferred← citeshttps://doi.org/10.1016/s0007-4551(23)00473-3openalex-snapshot
Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023
inferred← citeshttps://doi.org/10.1016/s0140-6736(24)00054-0openalex-snapshot
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
inferred← citeshttps://doi.org/10.1016/s0960-9776(19)31134-8openalex-snapshot
Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer
inferred← citeshttps://doi.org/10.1016/s1470-2045(18)30570-9openalex-snapshot
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
inferred← citeshttps://doi.org/10.1016/s1470-2045(24)00104-9openalex-snapshot
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
inferred← citeshttps://doi.org/10.1016/s1470-2045(25)00707-7openalex-snapshot
MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study
inferred← citeshttps://doi.org/10.1038/s41523-021-00342-5openalex-snapshot
A careful reassessment of anthracycline use in curable breast cancer
inferred← citeshttps://doi.org/10.1038/s41523-022-00380-7openalex-snapshot
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
inferred← citeshttps://doi.org/10.1038/s41523-024-00636-4openalex-snapshot
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
inferred← citeshttps://doi.org/10.1038/s41523-025-00742-xopenalex-snapshot
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer
inferred← citeshttps://doi.org/10.1038/s41523-025-00765-4openalex-snapshot
Inflammatory breast cancer, best practice in the community setting
inferred← citeshttps://doi.org/10.1038/s41571-024-00939-2openalex-snapshot
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
inferred← citeshttps://doi.org/10.1038/s41598-024-61562-wopenalex-snapshot
Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment
inferred← citeshttps://doi.org/10.1038/s41598-024-84039-2openalex-snapshot
The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis
inferred← citeshttps://doi.org/10.1038/s41598-025-31515-yopenalex-snapshot
Clinical characteristics and prognostic impact of HER2 low expression in breast cancer subtypes from a Brazilian real-world cohort
inferred← citeshttps://doi.org/10.1038/s43018-024-00749-6openalex-snapshot
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial
inferred← citeshttps://doi.org/10.1053/j.seminoncol.2020.08.001openalex-snapshot
Landmark trials in the medical oncology management of early stage breast cancer
inferred← citeshttps://doi.org/10.1055/a-1001-9925openalex-snapshot
Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer
inferred← citeshttps://doi.org/10.1055/a-1036-0961openalex-snapshot
Update Mammakarzinom 2019 Teil 4 – diagnostische und therapeutische Herausforderungen neuer personalisierter Therapien für Patientinnen mit frühem Mammakarzinom
inferred← citeshttps://doi.org/10.1056/nejmoa1814017openalex-snapshot
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1080/0284186x.2023.2202330openalex-snapshot
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
inferred← citeshttps://doi.org/10.1080/14656566.2025.2591813openalex-snapshot
Expanding indications and developmental landscape of HER2-targeted therapies in breast cancer: a pharmacotherapeutic perspective
inferred← citeshttps://doi.org/10.1080/14737140.2018.1477596openalex-snapshot
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects
inferred← citeshttps://doi.org/10.1080/14737140.2019.1596804openalex-snapshot
Oncologic therapies associated with cardiac toxicities: how to minimize the risks
inferred← citeshttps://doi.org/10.1080/14737140.2019.1596805openalex-snapshot
Pertuzumab for the treatment of breast cancer
inferred← citeshttps://doi.org/10.1080/14740338.2021.1983541openalex-snapshot
Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story
inferred← citeshttps://doi.org/10.1080/14740338.2026.2667402openalex-snapshot
Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies
inferred← citeshttps://doi.org/10.1093/annonc/mdx773openalex-snapshot
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
inferred← citeshttps://doi.org/10.1093/bjsopen/zrac028openalex-snapshot
Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1093/jnci/djac126openalex-snapshot
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab
inferred← citeshttps://doi.org/10.1093/oncolo/oyad160openalex-snapshot
A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequentialnab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1097/cad.0000000000001223openalex-snapshot
The relevance of macrocytosis induction during neoadjuvant dose-dense chemotherapy in breast cancer patients
inferred← citeshttps://doi.org/10.1097/cco.0000000000000492openalex-snapshot
Escalation and de-escalation in HER2 positive early breast cancer
inferred← citeshttps://doi.org/10.1097/coc.0000000000000816openalex-snapshot
Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States
inferred← citeshttps://doi.org/10.1097/coc.0000000000001102openalex-snapshot
Fulfilling the Role of a Parent While Undergoing Treatment for Cancer
inferred← citeshttps://doi.org/10.1097/md.0000000000022886openalex-snapshot
A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy
inferred← citeshttps://doi.org/10.1097/md.0000000000030000openalex-snapshot
Preventing effect of astragalus polysaccharide on cardiotoxicity induced by chemotherapy of epirubicin: A pilot study
inferred← citeshttps://doi.org/10.1111/ajco.70123openalex-snapshot
Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia
inferred← citeshttps://doi.org/10.1111/imj.14265openalex-snapshot
Demonstrating the feasibility of collecting secondary, de‐identified data on Australian patients receiving treatment as part of a Medicine Access Programme
inferred← citeshttps://doi.org/10.1111/pin.70119openalex-snapshot
Doublecortin‐Like Kinase 1 Expression in HER2‐Positive Breast Cancer: Relation to Clinicopathological Characteristics and Response to Subcutaneous Injection of Pertuzumab‐Trastuzumab (Phesgo) as a Part of Neoadjuvant Chemotherapy
inferred← citeshttps://doi.org/10.1136/esmoopen-2019-000659openalex-snapshot
Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials
inferred← citeshttps://doi.org/10.1155/2022/7146172openalex-snapshot
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
inferred← citeshttps://doi.org/10.1158/1078-0432.c.6530691.v1openalex-snapshot
Data from Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors
inferred← citeshttps://doi.org/10.1158/1078-0432.c.6533189openalex-snapshot
Data from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1158/1078-0432.c.6533189.v1openalex-snapshot
Data from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1158/1078-0432.c.6533189.v2openalex-snapshot
Data from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-20-4162openalex-snapshot
Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-22-1989openalex-snapshot
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1159/000492122openalex-snapshot
Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field
inferred← citeshttps://doi.org/10.1159/000501000openalex-snapshot
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019
inferred← citeshttps://doi.org/10.1159/000511925openalex-snapshot
Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer
inferred← citeshttps://doi.org/10.1159/000513766openalex-snapshot
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
inferred← citeshttps://doi.org/10.1159/000534626openalex-snapshot
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
inferred← citeshttps://doi.org/10.1159/000534670openalex-snapshot
HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation
inferred← citeshttps://doi.org/10.1161/cir.0000000000001056openalex-snapshot
Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association
inferred← citeshttps://doi.org/10.1177/03008916211067568openalex-snapshot
Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial
inferred← citeshttps://doi.org/10.1177/10732748231209193openalex-snapshot
Research Status of Systemic Adjuvant Therapy for Early Breast Cancer
inferred← citeshttps://doi.org/10.1177/1078155219857800openalex-snapshot
Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience
inferred← citeshttps://doi.org/10.1177/11795549231195293openalex-snapshot
The Value of Neoadjuvant Anthracycline-Based Regimens for HER2-Positive Breast Cancer: A Systematic Review and Meta-analysis Including 1366 Patients
inferred← citeshttps://doi.org/10.1177/15581551251403784openalex-snapshot
Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy
inferred← citeshttps://doi.org/10.1177/1758835920985632openalex-snapshot
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer
inferred← citeshttps://doi.org/10.1177/17588359211009003openalex-snapshot
Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial
inferred← citeshttps://doi.org/10.1177/17588359211066677openalex-snapshot
Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
inferred← citeshttps://doi.org/10.1177/17588359221106564openalex-snapshot
Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
inferred← citeshttps://doi.org/10.1177/17588359221113269openalex-snapshot
Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer
inferred← citeshttps://doi.org/10.1177/17588359231156146openalex-snapshot
Efficacy analysis of neoadjuvant chemotherapy with or without anthracyclines in female patients with HER2-positive breast cancer in China: a nationwide, multicenter, 10-year retrospective study (CSBrS-012)
inferred← citeshttps://doi.org/10.1186/s12885-022-09895-5openalex-snapshot
Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial
inferred← citeshttps://doi.org/10.1186/s12885-024-11871-0openalex-snapshot
Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
inferred← citeshttps://doi.org/10.1186/s12885-024-12506-0openalex-snapshot
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study
inferred← citeshttps://doi.org/10.1186/s12916-018-1233-1openalex-snapshot
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
inferred← citeshttps://doi.org/10.1186/s13058-023-01664-xopenalex-snapshot
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
inferred← citeshttps://doi.org/10.1186/s13643-025-03058-wopenalex-snapshot
Efficacy of dual HER2 blockade in neoadjuvant HER2-positive breast cancer: a meta-analysis of RCTs
inferred← citeshttps://doi.org/10.1186/s40959-020-00081-9openalex-snapshot
Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
inferred← citeshttps://doi.org/10.1188/19.onf.e145-e158openalex-snapshot
Anthracycline Chemotherapy–Induced Cardiotoxicity in Breast Cancer Survivors: A Systematic Review
inferred← citeshttps://doi.org/10.1200/edbk_432442openalex-snapshot
Systemic Therapy in Breast Cancer
inferred← citeshttps://doi.org/10.1200/go-24-00307openalex-snapshot
Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES Study
inferred← citeshttps://doi.org/10.1200/jco.2017.76.7863openalex-snapshot
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2–Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
inferred← citeshttps://doi.org/10.1200/jco.21.01059openalex-snapshot
Anthracyclines for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Are We Ready to Let Them Go?
inferred← citeshttps://doi.org/10.1200/jco.22.01816openalex-snapshot
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial
inferred← citeshttps://doi.org/10.1200/op.21.00274openalex-snapshot
Survival in the Real World: A National Analysis of Patients Treated for Early-Stage Breast Cancer
inferred← citeshttps://doi.org/10.1200/op.23.00494openalex-snapshot
Cardiotoxicity of Agents Used in Patients With Breast Cancer
inferred← citeshttps://doi.org/10.1245/s10434-026-19475-7openalex-snapshot
Is Neoadjuvant Chemotherapy Justified When Triple-Negative Breast Cancer or HER2-Positive Breast Cancer Presents as ≥1 cm of Only Calcifications or as a Subcentimeter Mass with Surrounding Calcifications?
inferred← citeshttps://doi.org/10.1248/bpb.b19-00876openalex-snapshot
Effects of Diluent Volume and Administration Time on the Incidence of Anaphylaxis Following Docetaxel Therapy in Breast Cancer
inferred← citeshttps://doi.org/10.1253/circrep.cr-25-0036openalex-snapshot
Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated With Trastuzumab and Pertuzumab
inferred← citeshttps://doi.org/10.12677/jcpm.2025.41064openalex-snapshot
Application Status of Neoadjuvant Targeted Drugs for HER-2 Positive Breast Cancer
inferred← citeshttps://doi.org/10.12703/r/10-2openalex-snapshot
Recent advances in neoadjuvant therapy for breast cancer
inferred← citeshttps://doi.org/10.1515/med-2026-1525openalex-snapshot
Neoadjuvant anthracycline-containing vs. anthracycline-free chemotherapy with dual HER2 blockade in HER2-Positive breast cancer: a Systematic Review and meta-analysis
inferred← citeshttps://doi.org/10.17650/1994-4098-2020-16-3-46-55openalex-snapshot
Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy
inferred← citeshttps://doi.org/10.20892/j.issn.2095-3941.2020.0157openalex-snapshot
Drug resistance gene expression and chemotherapy sensitivity detection in Chinese women with different molecular subtypes of breast cancer
inferred← citeshttps://doi.org/10.20935/acadonco7516openalex-snapshot
Redefining the role of anthracyclines in early breast cancer treatment
inferred← citeshttps://doi.org/10.21037/atm-23-1880openalex-snapshot
Survival outcomes of Zo-NAnTAx: a five-year analysis of zoledronic acid added to a neoadjuvant regimen for HER2-positive breast cancer
inferred← citeshttps://doi.org/10.21037/cco-21-122openalex-snapshot
What is the best treatment recommendation for HER2+ IBC with residual disease?—a narrative review
inferred← citeshttps://doi.org/10.21037/cco-21-81openalex-snapshot
What is the best systemic treatment for newly diagnosed inflammatory breast cancer?—a narrative review
inferred← citeshttps://doi.org/10.21037/gs-20-791openalex-snapshot
Neoadjuvant docetaxel with or without carboplatin plus dual HER2 blockade for HER2-positive breast cancer: a retrospective multi-center Chinese study
inferred← citeshttps://doi.org/10.21037/gs-21-794openalex-snapshot
Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study
inferred← citeshttps://doi.org/10.21037/gs-24-92openalex-snapshot
Successful treatment of enormous locally advanced breast cancer through neoadjuvant chemotherapy and surgical intervention: a case report
inferred← citeshttps://doi.org/10.21037/gs.2018.10.02openalex-snapshot
Primary medical therapy and breast conservation treatment: the medical oncology perspective
inferred← citeshttps://doi.org/10.21037/gs.2020.03.12openalex-snapshot
Neoadjuvant dual anti-HER2 therapy for early breast cancer: where do we stand?
inferred← citeshttps://doi.org/10.21037/tbcr-21-10openalex-snapshot
Optimizing HER2-positive breast cancer therapy through neoadjuvant platforms: controversies and concepts
inferred← citeshttps://doi.org/10.21037/tbcr-21-13openalex-snapshot
Updated interpretation for early breast cancer in The Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines
inferred← citeshttps://doi.org/10.21037/tcr-22-2547openalex-snapshot
Efficacy, cardiotoxicity and factors affecting pathologic complete response of neoadjuvant chemotherapy with anthracycline-containing verses anthracycline-free regimens plus dual HER2 blockade for HER2-positive early-stage breast cancer: a retrospective study
inferred← citeshttps://doi.org/10.21037/tcr.2019.05.04openalex-snapshot
Toward precision medicine in inflammatory breast cancer
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2054550/v1openalex-snapshot
The Impact of Neoadjuvant Systemic Treatment on Postoperative Complications in Breast Cancer Surgery
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2511860/v1openalex-snapshot
Evaluation Of The RDW Index (Red Cell Distribution Width) In The Prognosis Of Patients With Breast Cancer
inferred← citeshttps://doi.org/10.21203/rs.3.rs-3611567/v1openalex-snapshot
Comparison of the Efficacy and Safety of Docetaxel-Trastuzumab-Pertuzumab (DTP) with Standard 4-Doxorubicin and Cyclophosphamide (AC)-Taxan-Trastuzumab-Pertuzumab in Neoadjuvant Treatment of Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER-2) Positive Breast Cancer: a Turk Oncology…
showing the first 200 of 274 · page through all 274
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.